Print Page   |   Contact Us   |   Sign In
Engaging with Pharma Partners at M2D2
Page 1 of 1
Thread Actions

11/20/2019 at 4:47:10 PM GMT
Posts: 13
Engaging with Pharma Partners at M2D2




Join us at M2D2 for discussion around how and when startups should engage with pharma partners. Learn tips, best practices, and take advantage of great networking. Lunch will be provided.


Date: 12/10/2019

Time: 10:00AM – 3:00PM

Location: M2D2; 110 Canal Street, 4th Floor, Lowell, MA 01854



10:00- Check-in, Welcome & Introductions

10:30-11:45 – Panel presentation

11:45-1:00 – Lunch & Networking

1:00-3:00 – Optional private 1:1 meeting



Imran Nasrullah - Boehringer Ingelheim

Outcome driven biopharmaceutical leader, recognized for delivering innovation and being creative, dynamic, and cross functionally capable. Recipient of Boehringer Ingelheim's President Award. Extensive experience covering business development, alliance management, partnering and licensing activities in diagnostics, personalized medicine, therapeutics, and technology platforms with proven track record from Boehringer Ingelheim, Massbio, Genzyme Genetics, Millennium Pharmaceuticals.


Alex Lagadinos - Sarepta

PhD trained molecular biologist with an MBA-level education in bioscience management and over 10 years of experience in research and development. Proven track record of bridging discovery research with business development in order to align strategic initiatives and promote corporate development. Experience with inbound and outbound collaborative transactions and tacit knowledge in rare diseases. 


Jennifer Ma - Novartis Institutes for BioMedical Research (NIBR)

Jennifer joined the Novartis Institutes for BioMedical Research (NIBR) in 2015 focusing on licensing and transactions.  NIBR is the early R&D unit of Novartis, responsible for programs from drug discovery stage through early clinical development, covering all the therapeutic interest areas for Novartis. The licensing team establishes diverse kinds of collaborations with biotech companies and academics.  Prior to joining NIBR, Jennifer held progressively more senior business and licensing roles at AstraZeneca/Medimmune and 5AM Ventures, and started her career setting up a Novartis-academic spin-out.  She received a B.A. in Chemistry from Harvard University, a Ph.D. in organic chemistry from the California Institute of Technology, and an M.B.A. from Harvard Business School.


Ronald Dorenbos, Ph.D - Takeda Pharmaceuticals

As Head of Innovation Management and Scouting and as a member of Takeda’s Digital Strategy team Ronald helps Takeda with its technology and innovation strategy. Earlier, at the Life Science division of PA Consulting, Ronald led projects for some of the world’s top 10 pharmaceutical companies that included projects around strategy, commercialization and digital health and at his company BioFrontline he provides management, strategy and commercial advice to life sciences companies in the US, Europe and Asia.

After obtaining MAs in Biotechnology and Molecular Biology and a PhD in Pharmaceutical Biology at the University Medical Center Groningen in the Netherlands Ronald spent six years at Harvard studying Parkinson’s, Schizophrenia and the genetics of aggressive behavior, before making the transition to industry. As a consultant Ronald got involved in projects related to artificial intelligence and he has been following the field over the last 10 years. He is frequently invited to deliver presentations and keynotes related to AI in Pharma and Healthcare and has presented at numerous events internationally. He is also the founder of the LinkedIn groups ‘AI – Artificial Intelligence’, ‘Small Molecules’, ‘Boston Biotech’ and ‘Golden Triangle Biotech’ that serve over 10,000 members.



Event URL:


 Attached Images:

Membership Management Software Powered by YourMembership  ::  Legal